AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1798310 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements (three passive stretch trials)
Number of subjects: 60
Study 7208558 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg d-amphetamine
Number of subjects: 10
Study 30379314 — intervention group
Group type: EXPERIMENTAL
Intervention: 30,000 IU cholecalciferol/week for 6 months
Number of subjects: 115
Study 30379314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 26924941 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-case stapes surgery
Number of subjects: 112
Study 26924941 — intervention group
Group type: COMPARATOR
Intervention: Inpatient stapes surgery
Number of subjects: 112
Study 24641841 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary hypofractionated irradiation of the prostate with protons and carbon ions
Number of subjects: 92
Study 23164526 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative checklist
Number of subjects: 200
Study 23164526 — intervention group
Group type: COMPARATOR
Intervention: No preoperative checklist
Number of subjects: 200
Study 20215948 — intervention group
Group type: COMPARATOR
Intervention: Immediate pushing
Number of subjects: 44
Study 20215948 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed pushing
Number of subjects: 44
Study 17364906 — intervention group
Group type: EXPERIMENTAL
Intervention: Right median nerve stimulation (RMNS) for 30 min a day, 5 days a week, for 6 weeks
Number of subjects: 17
Study 17364906 — intervention group
Group type: COMPARATOR
Intervention: Sham RMNS for 30 min a day, 5 days a week, for 6 weeks
Number of subjects: 17
Study 15604945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 18F‐FDG PET with measured arterial input during hyperinsulinaemic euglycaemic clamping (group A)
Number of subjects: 15
Study 15604945 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic 18F‐FDG PET with estimated input from thoracic images and venous activity during late phase (group B)
Number of subjects: 15
Study 12066946 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mifepristone as a single dose
Number of subjects: 1000
Study 12066946 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen (two tablets each with 50 microg ethinyloestradiol and 0.25 mg levonorgestrel, repeated 12 hours later)
Number of subjects: 1000
Study 12066946 — intervention group
Group type: EXPERIMENTAL
Intervention: mifepristone
Number of subjects: 1000
Study 12066946 — intervention group
Group type: COMPARATOR
Intervention: Yuzpe regimen
Number of subjects: 1000
Study 9809007 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mental health system in Kawasaki
Number of subjects: 1250
Study 7649072 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily for 6 weeks
Number of subjects: 50
Study 2678424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times daily)
Number of subjects: 0
Study 2678424 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (150 mg three times daily)
Number of subjects: 0
Study 2678424 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate plus ranitidine
Number of subjects: 0
Study 2678424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate at lower pH (1 or 2)
Number of subjects: 0
Study 2678424 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine pretreatment
Number of subjects: 0
Study 31004139 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/d of DHA
Number of subjects: 200
Study 31004139 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 26974214 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable 50 mg
Number of subjects: 323
Study 26974214 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable 25 mg
Number of subjects: 323
Study 26974214 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injectable (both dosages)
Number of subjects: 323
Study 24272788 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible laryngoscopy performed by otolaryngologists with various degrees of experience
Number of subjects: 532
Study 24272788 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible laryngoscopy performed by experienced laryngologists
Number of subjects: 532
Study 24272788 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower levels of pain during laryngoscopy
Number of subjects: 532
Study 23394502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast dry syrup (PLK DS)
Number of subjects: 0
Study 23394502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20423844 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney‐Tonifying plus Blood‐Promoting Recipe
Number of subjects: 60
Study 20423844 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 60
Study 18681749 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (0.25-2 mg/day)
Number of subjects: 24
Study 18681749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15556128 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatiotemporal experience with locations (four sets of nearby locations learned together in time)
Number of subjects: 0
Study 15556128 — intervention group
Group type: EXPERIMENTAL
Intervention: New pattern of spatiotemporal experience introduced to adults
Number of subjects: 0
Study 15556128 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent new pattern of spatiotemporal organization for children
Number of subjects: 0
Study 15556128 — intervention group
Group type: EXPERIMENTAL
Intervention: Long delay after initial learning
Number of subjects: 0
Study 12705563 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer retribution scenarios (4 different scenarios)
Number of subjects: 2604
Study 9043896 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU FSH administered to husbands, either i.m. or s.c., three times a week, starting 3 months before IUI cycles and maintained until the fifth IUI cycle
Number of subjects: 148
Study 9043896 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 148
Study 9043896 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 IU FSH administered to husbands
Number of subjects: 148
Study 1759767 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 44
Study 1759767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 6176794 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 5 mg three times daily
Number of subjects: 8
Study 6176794 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg daily
Number of subjects: 8
Study 6176794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30628084 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D endoscope
Number of subjects: 92
Study 30628084 — intervention group
Group type: COMPARATOR
Intervention: 2D endoscope
Number of subjects: 92
Study 29088928 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (target serum concentration, 0.80-0.99 mEq/L)
Number of subjects: 224
Study 29088928 — intervention group
Group type: COMPARATOR
Intervention: Divalproex (target serum valproate concentration, 80-99 μg/mL)
Number of subjects: 224
Study 29088928 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive risperidone
Number of subjects: 224
Study 29088928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation
Number of subjects: 224
Study 29088928 — intervention group
Group type: EXPERIMENTAL
Intervention: Tremor
Number of subjects: 224
Study 29088928 — intervention group
Group type: EXPERIMENTAL
Intervention: Target concentrations achievement
Number of subjects: 224
Study 27881256 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Management Program (SMP)
Number of subjects: 90
Study 27881256 — intervention group
Group type: COMPARATOR
Intervention: Ordinary care (Control)
Number of subjects: 90
Study 25103148 — intervention group
Group type: COMPARATOR
Intervention: Imiquimod, 5%, cream (44 patients)
Number of subjects: 89
Study 25103148 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional Mycobacterium w (Mw) vaccine (45 patients)
Number of subjects: 89
Study 22552800 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NMR
Number of subjects: 43
Study 22552800 — intervention group
Group type: EXPERIMENTAL
Intervention: NMR in plasma and saliva
Number of subjects: 43
Study 22552800 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood NMR
Number of subjects: 43
Study 19170911 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) after electrical cardioversion (CV)
Number of subjects: 26
Study 19170911 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal-averaged electrocardiography (SAECG) after CV
Number of subjects: 26
Study 19170911 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography after CV
Number of subjects: 26
Study 19170911 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetocardiography (MCG) after 1 month in SR
Number of subjects: 26
Study 19170911 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched subjects without history of AF)
Number of subjects: 26
Study 17586422 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids (PUFAs) 1.7 g
Number of subjects: 30
Study 17586422 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (olive oil)
Number of subjects: 30
Study 14513268 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 microg) plus calcium (500 mg)
Number of subjects: 204
Study 14513268 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D (1000 IU) plus calcium (500 mg)
Number of subjects: 204
Study 11688520 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) plus Epirubicin (E) plus Taxol (T) (GET)
Number of subjects: 36
Study 11688520 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose chemotherapy (HDCT) after GET
Number of subjects: 36
Study 11688520 — intervention group
Group type: EXPERIMENTAL
Intervention: GET
Number of subjects: 36
Study 9679578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hangeshashin-to (TJ-14)
Number of subjects: 41
Study 9679578 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 41
Study 8851643 — intervention group
Group type: EXPERIMENTAL
Intervention: Midday light therapy
Number of subjects: 9
Study 8851643 — intervention group
Group type: COMPARATOR
Intervention: Morning light therapy
Number of subjects: 9
Study 8851643 — intervention group
Group type: COMPARATOR
Intervention: Evening light therapy
Number of subjects: 9
Study 8851643 — intervention group
Group type: COMPARATOR
Intervention: Light treatment (general)
Number of subjects: 9
Study 2256863 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use for 6 months
Number of subjects: 46
Study 2256863 — intervention group
Group type: COMPARATOR
Intervention: Non-condom use for 6 months
Number of subjects: 46
Study 540522 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% clobetasone butyrate cream
Number of subjects: 48
Study 540522 — intervention group
Group type: COMPARATOR
Intervention: 0.1% betamethasone valerate
Number of subjects: 48
Study 31026433 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 170
Study 31026433 — intervention group
Group type: COMPARATOR
Intervention: Open esophagectomy
Number of subjects: 170
Study 29273759 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) condition using a head-mounted display (HMD) and customized manual wheelchair for self-movement.
Number of subjects: 0
Study 29273759 — intervention group
Group type: COMPARATOR
Intervention: Real room condition (implied control group).
Number of subjects: 0
Study 25637340 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast radiotherapy (40-50 Gy in 15-25 fractions)
Number of subjects: 1326
Study 25637340 — intervention group
Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 1326
Study 25637340 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-breast radiotherapy
Number of subjects: 1326
Study 24629635 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptamer-based proteomic technology
Number of subjects: 39
Study 24629635 — intervention group
Group type: EXPERIMENTAL
Intervention: A logistic regression model combining markers associated with 8-week culture status
Number of subjects: 39
Study 24629635 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional markers
Number of subjects: 39
Study 21926601 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone 200 mg/day (HC group)
Number of subjects: 99
Study 21926601 — intervention group
Group type: COMPARATOR
Intervention: Saline serum (control group)
Number of subjects: 99
Study 19036894 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CHO (1.2 g CHO + 0.4 g protein x kg(‐1) x h(‐1))
Number of subjects: 6
Study 19036894 — intervention group
Group type: EXPERIMENTAL
Intervention: PRO-CHO
Number of subjects: 6
Study 19036894 — intervention group
Group type: COMPARATOR
Intervention: L-CHO (1.2 g CHO x kg(‐1) x h(‐1))
Number of subjects: 6
Study 19036894 — intervention group
Group type: COMPARATOR
Intervention: H-CHO (1.6 g CHO x kg(‐1) x h(‐1))
Number of subjects: 6
Study 19036894 — intervention group
Group type: COMPARATOR
Intervention: 1.2 g CHO x kg(‐1) x h(‐1)
Number of subjects: 6
Study 17434014 — intervention group
Group type: EXPERIMENTAL
Intervention: Quin-Lng (levonorgestrel 6 mg)
Number of subjects: 0
Study 17434014 — intervention group
Group type: EXPERIMENTAL
Intervention: Quin-Ng (quinestrol 3 mg and norgestrel 12 mg)
Number of subjects: 0
Study 17434014 — intervention group
Group type: EXPERIMENTAL
Intervention: Quin-Ng and Quin-Lng
Number of subjects: 0
Study 15005721 — intervention group
Group type: EXPERIMENTAL
Intervention: RAB3A gene mutation screening
Number of subjects: 47
Study 11307656 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (1.5 mg.kg‐1)
Number of subjects: 80
Study 11307656 — intervention group
Group type: COMPARATOR
Intervention: Propacetamol (2 g)
Number of subjects: 80
Study 9720832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (200 microg intranasal, twice a day for 6 months)
Number of subjects: 55
Study 10476618 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 500
Study 10476618 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 500
Study 10476618 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 500
Study 1974998 — intervention group
Group type: EXPERIMENTAL
Intervention: CAGE questionnaire
Number of subjects: 915
Study 1974998 — intervention group
Group type: COMPARATOR
Intervention: Computer-assisted laboratory profiles
Number of subjects: 915
Study 364370 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin
Number of subjects: 0
Study 364370 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31502659 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior 90° partial fundoplication
Number of subjects: 191
Study 31502659 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 191
Study 31502659 — intervention group
Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 191
Study 30954360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenobarbital (PB) at 10 mg/kg
Number of subjects: 24
Study 30954360 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml of normal saline)
Number of subjects: 24
Study 30954360 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous phenobarbital (PB) at 10 mg/kg (after placebo failure)
Number of subjects: 24
Study 28950681 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening at ages 35-39 and biennial from 41-49
Number of subjects: 0
Study 28950681 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual screening from 38-42 and triennial from 43-58
Number of subjects: 0
Study 28950681 — intervention group
Group type: EXPERIMENTAL
Intervention: Biennial screening from 40-60 years of age
Number of subjects: 0
Study 26180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated consent and data collection processes
Number of subjects: 0
Study 26180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of participants' own computer equipment and reliance on big data for outcomes
Number of subjects: 0
Study 26180952 — intervention group
Group type: EXPERIMENTAL
Intervention: Outsourcing of costly tasks
Number of subjects: 0
Study 23867733 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (positive instructions of pain relief)
Number of subjects: 36
Study 23867733 — intervention group
Group type: COMPARATOR
Intervention: Nocebo group (negative instructions of pain increase)
Number of subjects: 36
Study 21576110 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal intraparietal sulcus lesion (Case H.H.)
Number of subjects: 2
Study 21576110 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal intraparietal sulcus lesion (Case N.V.)
Number of subjects: 2
Study 21576110 — intervention group
Group type: COMPARATOR
Intervention: Inferior parietal lesion group
Number of subjects: 2
Study 21576110 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 2
Study 21576110 — intervention group
Group type: EXPERIMENTAL
Intervention: Event-related functional MRI (Case H.H.)
Number of subjects: 2
Study 21576110 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state functional MRI (Case H.H.)
Number of subjects: 2
Study 19366489 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (partial agonist)
Number of subjects: 0
Study 19366489 — intervention group
Group type: COMPARATOR
Intervention: Antagonist antipsychotics (risperidone or olanzapine)
Number of subjects: 0
Study 16955110 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime/heparin lock (group I)
Number of subjects: 109
Study 14758576 — intervention group
Group type: EXPERIMENTAL
Intervention: Older bipolar subjects
Number of subjects: 36
Study 14758576 — intervention group
Group type: EXPERIMENTAL
Intervention: Late-onset bipolar subjects
Number of subjects: 36
Study 11211363 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA behavioral and medication treatments
Number of subjects: 579
Study 11211363 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA medication treatments (with or without behavioral treatments)
Number of subjects: 579
Study 11211363 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (medication and behavioral) treatments
Number of subjects: 579
Study 9250633 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic transthoracic defibrillation (115 J)
Number of subjects: 30
Study 9250633 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic transthoracic defibrillation (130 J)
Number of subjects: 30
Study 9250633 — intervention group
Group type: COMPARATOR
Intervention: Monophasic damped-sine wave shock (200 J)
Number of subjects: 30
Study 9250633 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 30
Study 9250633 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal shock
Number of subjects: 30
Study 7945622 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine response to systemic infection (TNF-alpha, IL-1 alpha, IL-1 beta, IL-6)
Number of subjects: 0
Study 2899236 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetylsalicylic acid (ASA) orally starting 12 h after admission and then intermittently every third day for one month
Number of subjects: 20
Study 2899236 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 20
Study 2899236 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg acetylsalicylic acid (ASA)
Number of subjects: 20
Study 31569180 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational pain management intervention
Number of subjects: 42
Study 31569180 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 42
Study 30922297 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg orally once daily for 6 weeks
Number of subjects: 58
Study 30922297 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 28610601 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-down positioning for at least 8 hours a day for 5 days post-surgery
Number of subjects: 192
Study 28610601 — intervention group
Group type: COMPARATOR
Intervention: Face-forward positioning for at least 8 hours a day for 5 days post-surgery
Number of subjects: 192
Study 25193578 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative contrast-enhanced computerized tomography (CECT) in DTC patients
Number of subjects: 128
Study 25193578 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative contrast-enhanced computerized tomography (CECT) in benign goiter patients
Number of subjects: 128
Study 25193578 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative contrast-enhanced computerized tomography (CECT) in patients with non-thyroidal diseases
Number of subjects: 128
Study 25193578 — intervention group
Group type: COMPARATOR
Intervention: Control groups without CECT (DTC patients not undergoing CECT, benign goiter patients not undergoing CECT, and patients with non-thyroidal diseases not undergoing CECT)
Number of subjects: 128
Study 23237211 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized one‐to‐one activities using Montessori principles
Number of subjects: 44
Study 23237211 — intervention group
Group type: COMPARATOR
Intervention: Non‐personalized activity (control)
Number of subjects: 44
Study 21493423 — intervention group
Group type: EXPERIMENTAL
Intervention: KTP laser IT surgery
Number of subjects: 35
Study 21493423 — intervention group
Group type: COMPARATOR
Intervention: INCS
Number of subjects: 35
Study 19661078 — intervention group
Group type: EXPERIMENTAL
Intervention: CARET intervention (30 mg beta-carotene + 25,000 IU retinyl palmitate) with additional supplements
Number of subjects: 890
Study 19661078 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintervention phase (CARET + other supplements)
Number of subjects: 890
Study 19661078 — intervention group
Group type: COMPARATOR
Intervention: CARET intervention (30 mg beta-carotene + 25,000 IU retinyl palmitate)
Number of subjects: 890
Study 16961710 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium vaccae (1 mg)
Number of subjects: 166
Study 16961710 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed Mycobacterium vaccae (0.1 mg)
Number of subjects: 166
Study 16961710 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166